Open AccessPharmacologic Agents in the Management of Hypertension—Nisoldipine Coat‐Core
Author(s) -
White William B.
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.06628.x
Subject(s) - nisoldipine , medicine , amlodipine , dihydropyridine , tolerability , felodipine , pharmacology , blood pressure , calcium , nifedipine , adverse effect
Nisoldipine coat‐core (CC), a 1,4‐dihydropyridine calcium antagonist, is indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents. The CC technology allows for extended delivery of the drug and once‐daily dosing. Nisoldipine CC tablets are absorbed across the entire gastrointestinal tract, including the colon. Eighty percent of the total dose is in the slow‐release outer coat, while the core has immediate‐release characteristics suitable for absorption in the distal gastrointestinal tract. Numerous double‐blind, randomized studies of this agent have been done in patients with hypertension. The use of nisoldipine CC reduced both clinic and ambulatory blood pressure to a similar degree when compared with angiotensin‐converting enzyme (ACE) inhibitors, β‐blockers, and the calcium antagonists amlodipine and felodipine. The drug has also been studied in hypertensive African Americans and demonstrated equivalent efficacy to amlodipine. Tolerability of the drug is good, with the most common side effect of edema at a rate similar to other dihydropyridine calcium antagonists. Thus, results of more than a decade of clinical trial data support the use of nisoldipine CC as once‐daily therapy for the treatment of hypertension.